Fluorescence in situ hybridization: a multitarget approach in diagnosis and management of urothelial cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer – a comprehensive review of the published literature. Pharmacoeconomics21(18), 1315–1330 (2003).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Euro. Urol.49(3), 466–477 (2006).
   PubMed Web of Science ®Google Scholar
• van Rhijn BWG, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Euro. Urol.47(6), 736–748 (2005).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA293(7), 810–816 (2005).
   PubMed Web of Science ®Google Scholar
• Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol.164(5), 1768–1775 (2000).
   PubMed Web of Science ®Google Scholar
• Langbein S, Lehmann J, Harder A et al. Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique. Technol. Cancer Res. Treat.5(1), 67–71 (2006).
   PubMed Web of Science ®Google Scholar
• Seripa D, Parrella P, Gallucci M et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int. J. Cancer95(6), 364–369 (2001).
   PubMed Web of Science ®Google Scholar
• Wild PJ, Herr A, Wissmann C et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin. Cancer Res.11(12), 4415–4429 (2005).
   PubMed Web of Science ®Google Scholar
• Glas AS, Roos D, Deutekom M et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J. Urol.169(6), 1975–1982 (2003).
   PubMed Web of Science ®Google Scholar
• Kriegmair M, Zaak D, Stepp H et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Euro. Urol.36(5), 386–392 (1999).
   PubMed Web of Science ®Google Scholar
• Gaston KE, Pruthi RS. Value of urinary cytology in the diagnosis and management of urinary tract malignancies. Urology63(6), 1009–1016 (2004).
   Google Scholar
• Karakiewicz PI, Benayoun S, Zippe C et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int.97(5), 997–1001 (2006).
   Google Scholar
• Sokolova IA, Halling KC, Jenkins RB et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J. Mol. Diagn.2(3), 116–123 (2000).
   PubMed Web of Science ®Google Scholar
• Halling KC. Vysis (R) UroVysion for the detection of urothelial carcinoma. Expert Rev. Mol. Diagn.3(4), 507–519 (2003).
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Grilli B, Sauter G et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am. J. Clin. Pathol.116(1), 79–86 (2001).
   PubMed Web of Science ®Google Scholar
• Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: a FISH study. Urology65(5), 913–8 (2005).
   Google Scholar
• Bollmann V, Heller H, Bankfalvi A, Griefingholt H, Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients wit superficial bladder cancer? BJU Int.95(9), 1219–1225 (2005).
   Google Scholar
• Okamura T, Umemoto Y, Yasui T et al. Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization. Int. J. Clin. Oncol.9(5), 373–377 (2004).
   Google Scholar
• Degtyar P, Neulander E, Zirkin H et al. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Urology63(2), 398–401 (2004).
   Google Scholar
• Zellweger T, Benz G, Cathomas G et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int. J. Cancer119(7), 1660–1165 (2006).
   PubMed Web of Science ®Google Scholar
• Richter J, Jiang F, Gorog JP et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res.57(14), 2860–2864 (1997).
   PubMed Web of Science ®Google Scholar
• Bittard H, Lamy B, Billery C. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J. Urol.155(6), 1887–1891 (1996).
   PubMed Web of Science ®Google Scholar
• Skacel M, Fahmy M, Brainard JA et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J. Urol.169(6), 2101–5 (2003).
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol.168(5), 1950–1954 (2002).
   PubMed Web of Science ®Google Scholar
• Veeramachaneni R, Nordberg ML, Shi RH, Herrera GA, Turbat-Herrera EA. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn. Cytopathol.28(6), 301–307 (2003).
   Google Scholar
• Jones JS. DNA-based molecular cytology for bladder cancer surveillance. Urology67(3A), 35–45 (2006).
   PubMedGoogle Scholar
• Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Euro. Urol.42(6), 547–552 (2002).
   PubMed Web of Science ®Google Scholar
• Pode D, Shapiro A, Wald M et al. Noninvasive detection of bladder cancer with the BTA stat test. J. Urol.161(2), 443–446 (1999).
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Toma MI, Hellstern A et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int.92(9), 911–914 (2003).
   PubMed Web of Science ®Google Scholar
• Halling KC, King W, Sokolova IA et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and vysis urovysion assays for the detection of urothelial carcinoma in urine. J. Urol.167(5), 2001–2006 (2002).
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Hudson MA, Ellis WJ et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology50(3), 349–353 (1997).
   PubMed Web of Science ®Google Scholar
• Wiener HG, Mian C, Haitel A et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J. Urol.159(6), 1876–1880 (1998).
   PubMed Web of Science ®Google Scholar
• Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology50(6), 882–887 (1997).
   PubMed Web of Science ®Google Scholar
• Heicappell R, Wettig IC, Schostak M et al. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Euro. Urol.35(1), 81–87 (1999).
   Google Scholar
• Mahnert B, Tauber S, Kriegmair M et al. BTA-TRAK (TM) – A useful diagnostic tool in urinary bladder cancer? Anticancer Res.19(4A), 2615–2619 (1999).
   Google Scholar
• Thomas L, Leyh H, Marberger M et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin. Chem.45(4), 472–477 (1999).
   PubMed Web of Science ®Google Scholar
• Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol. Oncol.22(1), 16–19 (2004).
   Google Scholar
• Eble JN, Sauter G, EpsteinJI, Sesterhenn IA. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, France (2004).
   Google Scholar